Displaying items by tag: immunisation

Covid infections are increasing across the UK with about one in 25 people infected, according to the latest estimates from the Office for National Statistics (ONS). In Scotland, 300,000 people - one in 18 - have coronavirus, the highest level recorded during the pandemic. A sub-variant of Omicron, called BA2, is now thought to be the most common strain in most of the UK. Recent easing of restrictions and waning immunity from the vaccines could all be factors in the increase. Health secretary Sajid Javid said Omicron had been the last variant to be a concern, and the country had ‘successfully navigated’ it, but the Government continued to monitor the situation ‘very carefully’. The ONS infection survey tests thousands of people randomly in households across the UK and estimated 2.6 million people tested positive in the week ending 5 March. It was 2.4 million the week before.

The war in Ukraine has taken a lot of attention away from Covid, which is unfortunate because the pandemic has now killed almost six million people. There are countries where vaccination rates are still very low; this includes most African countries, where people should not be complacent as the virus still poses a grave risk. Africa’s top public health agency has signed a memorandum of understanding with Pfizer to bring supplies of the pharmaceutical firm’s Paxlovid antiviral pills to the continent. Also Moderna will build its first facility in Rwanda to sell, package, and distribute Johnson & Johnson Covid-19 vaccines.

Safety trials are underway for a Cambridge-led vaccine that could be used as a booster targeting Covid variants which threaten future coronavirus pandemics. The first volunteer received the vaccine on 14 December through a needle-free ‘injection’ - a blast of air that delivers it into the skin. This offers a possible future alternative to people who fear needle-based jabs. If it is successful it could be scaled up and manufactured as a powder to boost global vaccination efforts, particularly in low and middle-income countries. As new variants emerge there is a need for newer technologies. It’s vital that science continues to develop new generation vaccines. Pray for this new trial to lead the way for vaccines that will prime the immune system to respond with broader, stronger protection. The vaccine trial will follow up volunteers for about a year to ensure it is safe.